Zulvac 1 Bovis

RSS

Withdrawn

This medicine's authorisation has been withdrawn

inactivated bluetongue virus, serotype 1
MedicineVeterinaryWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Zulvac 1 Bovis has been withdrawn at the request of the marketing authorisation holder.

български (BG) (509.58 kB - PDF)

Bekijk

español (ES) (384.95 kB - PDF)

Bekijk

čeština (CS) (451.17 kB - PDF)

Bekijk

dansk (DA) (381.07 kB - PDF)

Bekijk

Deutsch (DE) (409.83 kB - PDF)

Bekijk

eesti (ET) (379.73 kB - PDF)

Bekijk

ελληνικά (EL) (514.35 kB - PDF)

Bekijk

français (FR) (409.54 kB - PDF)

Bekijk

italiano (IT) (408.74 kB - PDF)

Bekijk

latviešu (LV) (471.49 kB - PDF)

Bekijk

lietuvių (LT) (435.02 kB - PDF)

Bekijk

magyar (HU) (456.96 kB - PDF)

Bekijk

Malti (MT) (438.24 kB - PDF)

Bekijk

Nederlands (NL) (385.42 kB - PDF)

Bekijk

polski (PL) (464.22 kB - PDF)

Bekijk

português (PT) (408.96 kB - PDF)

Bekijk

română (RO) (415.31 kB - PDF)

Bekijk

slovenčina (SK) (436.84 kB - PDF)

Bekijk

slovenščina (SL) (455.38 kB - PDF)

Bekijk

suomi (FI) (403.39 kB - PDF)

Bekijk

svenska (SV) (384.08 kB - PDF)

Bekijk

Product information

български (BG) (735.77 kB - PDF)

Bekijk

español (ES) (588.23 kB - PDF)

Bekijk

čeština (CS) (780.58 kB - PDF)

Bekijk

dansk (DA) (591.89 kB - PDF)

Bekijk

Deutsch (DE) (573.04 kB - PDF)

Bekijk

eesti (ET) (586.69 kB - PDF)

Bekijk

ελληνικά (EL) (905.3 kB - PDF)

Bekijk

français (FR) (614.9 kB - PDF)

Bekijk

hrvatski (HR) (652.84 kB - PDF)

Bekijk

italiano (IT) (604.98 kB - PDF)

Bekijk

latviešu (LV) (807.34 kB - PDF)

Bekijk

lietuvių (LT) (651.56 kB - PDF)

Bekijk

magyar (HU) (796.39 kB - PDF)

Bekijk

Malti (MT) (798.16 kB - PDF)

Bekijk

Nederlands (NL) (607.21 kB - PDF)

Bekijk

polski (PL) (780.98 kB - PDF)

Bekijk

português (PT) (603.86 kB - PDF)

Bekijk

română (RO) (667.48 kB - PDF)

Bekijk

slovenčina (SK) (811.09 kB - PDF)

Bekijk

slovenščina (SL) (776.57 kB - PDF)

Bekijk

suomi (FI) (586.27 kB - PDF)

Bekijk

svenska (SV) (591.79 kB - PDF)

Bekijk

Íslenska (IS) (595.81 kB - PDF)

Bekijk

norsk (NO) (604.74 kB - PDF)

Bekijk
Latest procedure affecting product information:IB/00017
21/06/2019

български (BG) (230.28 kB - PDF)

Bekijk

español (ES) (343.83 kB - PDF)

Bekijk

čeština (CS) (369.47 kB - PDF)

Bekijk

dansk (DA) (347.52 kB - PDF)

Bekijk

Deutsch (DE) (348.53 kB - PDF)

Bekijk

eesti (ET) (355.15 kB - PDF)

Bekijk

ελληνικά (EL) (383.16 kB - PDF)

Bekijk

français (FR) (344.14 kB - PDF)

Bekijk

hrvatski (HR) (356.23 kB - PDF)

Bekijk

italiano (IT) (357.42 kB - PDF)

Bekijk

latviešu (LV) (383.76 kB - PDF)

Bekijk

lietuvių (LT) (373.86 kB - PDF)

Bekijk

magyar (HU) (368 kB - PDF)

Bekijk

Malti (MT) (387.39 kB - PDF)

Bekijk

Nederlands (NL) (347.91 kB - PDF)

Bekijk

polski (PL) (386.15 kB - PDF)

Bekijk

português (PT) (356.42 kB - PDF)

Bekijk

română (RO) (360.37 kB - PDF)

Bekijk

slovenčina (SK) (371.83 kB - PDF)

Bekijk

slovenščina (SL) (382.39 kB - PDF)

Bekijk

suomi (FI) (346.35 kB - PDF)

Bekijk

svenska (SV) (359.59 kB - PDF)

Bekijk

Íslenska (IS) (322.68 kB - PDF)

Bekijk

norsk (NO) (343.71 kB - PDF)

Bekijk

Product details

Name of medicine
Zulvac 1 Bovis
Active substance
inactivated bluetongue virus, serotype 1
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype 1
Species
Cattle
Anatomical therapeutic chemical veterinary (ATCvet) code
QI02AA08

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of cattle from 2½ months of age for the prevention of viraemia caused by bluetongue virus, serotype 1.

Onset of immunity: 15 days after completion of the primary vaccination course.

Duration of immunity: 12 months.

Authorisation details

EMA product number
EMEA/V/C/002334

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Marketing authorisation holder
Zoetis Belgium SA

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Marketing authorisation issued
05/08/2011
Revision
7

Assessment history

This page was last updated on

Share this page